Sign in Subscribe
Genetic research

Breakthrough in Gene Therapy for GM2 Gangliosidosis Diseases

Strategic Insights

— 1 min read

Researchers at UMass Chan Medical School have made significant progress in developing a gene therapy for GM2 gangliosidosis diseases, including Tay-Sachs and Sandhoff diseases. A Phase I/II clinical trial successfully demonstrated biochemical correction of the disease with minimal adverse reactions. Trial participants maintained oral feeding for longer periods and experienced fewer and more controllable seizures.

Key Takeaways:

  • The trial showed that patients with GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, can experience biochemical correction of the disease with minimal adverse reactions.
  • Participants maintained oral feeding for longer periods, with half of the cohorts remaining on full oral feeds for at least 25 months.
  • The study demonstrated that a hybrid approach using two harmless viral vectors can deliver DNA instructions to brain cells, teaching them to produce the missing HexA enzyme.
  • Clinical tests showed that production of the HexA enzyme increased for all participants, surpassing two times the lower limit of normal.
  • Participants experienced later onset of seizures, which were less severe, less frequent, and more responsive to anti-convulsant medication.

Statistics:

  • Nine participants in four cohorts were treated in the current study, with the administered dosage doubling for every cohort.
  • Half of the cohorts remained on full oral feeds for at least 25 months, with the two highest dose participants remaining on oral feeds until the end of the study (27 and 20 months respectively).
  • Clinical tests showed that production of the HexA enzyme increased for all participants, with activity surpassing two times the lower limit of normal.
  • Participants experienced fewer seizures, with 33% experiencing seizures at the end of the study compared to 100% at the beginning.

Sources:

  • UMass Chan Medical School
  • National Tay-Sachs & Allied Diseases Association
  • Cure Tay-Sachs Foundation
  • Matthew Forbes Romer Foundation
  • Blu Genes Foundation

Read more